FOLFIRINOX de-escalation in advanced pancreatic cancer: a multicenter real-life study.

Fiche publication


Date publication

septembre 2020

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr VERNEREY Dewi, Dr VIENOT Angélique, Mme MEURISSE Aurélia


Tous les auteurs :
Chevalier H, Vienot A, Lièvre A, Edeline J, El Hajbi F, Peugniez C, Vernerey D, Meurisse A, Hammel P, Neuzillet C, Borg C, Turpin A

Résumé

Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5FU, folinic acid, irinotecan, and oxaliplatin) induction chemotherapy (CT) followed by de-escalation as a maintenance strategy for advanced pancreatic cancer (aPC).

Mots clés

FOLFIRINOX, advanced pancreatic cancer, maintenance treatment, quality of life, real-life study

Référence

Oncologist. 2020 Sep 4;: